
## Gilberto Filaci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/691677/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell, 2022, 185, 847-859.e11.	28.9	590
2	Development of a TÂcell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status. Cell Host and Microbe, 2022, 30, 388-399.e3.	11.0	26
3	Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors. International Journal of Molecular Sciences, 2022, 23, 7155.	4.1	31
4	Dysregulation in B ell responses and T follicular helper cell function in ADA2 deficiency patients. European Journal of Immunology, 2021, 51, 206-219.	2.9	29
5	How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma. Cancers, 2021, 13, 2043.	3.7	18
6	Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28â^' T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer. Cancers, 2021, 13, 2234.	3.7	8
7	Singleâ€nucleotide polymorphisms in 3′â€untranslated region inducible costimulator gene and the important roles of miRNA in alopecia areata. Skin Health and Disease, 2021, 1, e34.	1.5	7
8	Characterization of T lymphocytes in severe COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 5608-5613.	5.0	24
9	Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. Immunity, 2021, 54, 1186-1199.e7.	14.3	71
10	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunology, Immunotherapy, 2021, 70, 3679-3692.	4.2	15
11	IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells. Cancers, 2021, 13, 4011.	3.7	3
12	Increased frequency of interleukinâ€4 and reduced frequency of interferonâ€Î³ and ILâ€17â€producing CD4+ and CD8+ cells in scleromyxedema. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1092-1097.	2.4	8
13	Anti-Cancer Immunotherapies Targeting Telomerase. Cancers, 2020, 12, 2260.	3.7	34
14	Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells. Cancers, 2020, 12, 488.	3.7	14
15	Dopamine inhibits human CD8+ Treg function through D1-like dopaminergic receptors. Journal of Neuroimmunology, 2019, 332, 233-241.	2.3	24
16	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. Journal of Virus Eradication, 2019, 5, 47-49.	0.5	0
17	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. Journal of Virus Eradication, 2019, 5, 47-49.	0.5	0
18	Beyond APECED: An update on the role of the autoimmune regulator gene (AIRE) in physiology and disease. Autoimmunity Reviews, 2018, 17, 325-330.	5.8	27

#	Article	IF	CITATIONS
19	White matter microstructure alterations correlate with terminally differentiated CD8+ effector T cell depletion in the peripheral blood in mania: Combined DTI and immunological investigation in the different phases of bipolar disorder. Brain, Behavior, and Immunity, 2018, 73, 192-204.	4.1	30
20	CD8+CD28â^'CD127loCD39+ regulatory T-cell expansion: AÂnew possible pathogenic mechanism for HIV infection?. Journal of Allergy and Clinical Immunology, 2018, 141, 2220-2233.e4.	2.9	22
21	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. Frontiers in Immunology, 2018, 9, 2447.	4.8	1
22	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naÃ <sup>-</sup> ve, HIV-1-infected patients. HIV Clinical Trials, 2018, 19, 158-162.	2.0	2
23	A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response. Scientific Reports, 2017, 7, 6286.	3.3	46
24	Phenotypic Alterations Involved in CD8+ Treg Impairment in Systemic Sclerosis. Frontiers in Immunology, 2017, 8, 18.	4.8	15
25	AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget, 2016, 7, 60872-60884.	1.8	8
26	Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients. Clinical and Experimental Medicine, 2016, 16, 407-412.	3.6	8
27	Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence. Oncotarget, 2016, 7, 6424-6435.	1.8	22
28	B cells characterization in ADA2 Deficiency patients. Pediatric Rheumatology, 2015, 13, .	2.1	1
29	Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system. HIV Clinical Trials, 2015, 16, 190-196.	2.0	7
30	Nanoparticles increase the efficacy of cancer chemopreventive agents in cells exposed to cigarette smoke condensate. Carcinogenesis, 2015, 36, 368-377.	2.8	17
31	Early and repeated IgG1Fc-pCons chimera vaccinations (GX101) improve the outcome in SLE-prone mice. Clinical and Experimental Medicine, 2015, 15, 255-260.	3.6	5
32	Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. Human Vaccines and Immunotherapeutics, 2015, 11, 838-850.	3.3	26
33	Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL. Journal of the International AIDS Society, 2014, 17, 19718.	3.0	2
34	Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients. Aids, 2014, 28, 1071-1074.	2.2	5
35	Single nucleotide polymorphisms in the promoter regions of Foxp3 and ICOSLG genes are associated with Alopecia Areata. Clinical and Experimental Medicine, 2014, 14, 91-97.	3.6	33
36	Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity. Cancer Immunology, Immunotherapy, 2014, 63, 501-511.	4.2	21

#	Article	IF	CITATIONS
37	ImmunoDB: a web based tool to analyze preclinical data. Studies in Health Technology and Informatics, 2014, 205, 438-42.	0.3	2
38	Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. Journal of Translational Medicine, 2013, 11, 120.	4.4	18
39	Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. Journal of NeuroImmune Pharmacology, 2013, 8, 1106-1113.	4.1	69
40	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1041-1052.	4.2	55
41	CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunology, Immunotherapy, 2013, 62, 851-862.	4.2	56
42	Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis. Human Immunology, 2013, 74, 166-169.	2.4	24
43	Metformin selectively affects human glioblastoma tumor-initiating cell viability. Cell Cycle, 2013, 12, 145-156.	2.6	154
44	Bioactive surfaces for antibody-antigen complex detection by Atomic Force Microscopy. Journal of Physics: Conference Series, 2013, 439, 012001.	0.4	13
45	Generation of more effective cancer vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 2543-2547.	3.3	11
46	The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials. Medicine 2 0, 2013, 2, e5.	2.4	22
47	Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmunity Reviews, 2012, 12, 300-304.	5.8	70
48	Cyclophosphamide inhibits the generation and function of CD8+ regulatory T cells. Human Immunology, 2012, 73, 207-213.	2.4	27
49	Abscisic acid ameliorates the systemic sclerosis fibroblast phenotype in vitro. Biochemical and Biophysical Research Communications, 2012, 422, 70-74.	2.1	19
50	CD8 <sup>+</sup> T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity. Autoimmunity, 2011, 44, 51-57.	2.6	42
51	Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clinical Immunology, 2011, 139, 249-257.	3.2	105
52	Th17 cells and allergic rhinitis: Is there clinical relevance?. Otolaryngology - Head and Neck Surgery, 2010, 143, 604-605.	1.9	8
53	The role of AIRE polymorphisms in melanoma. Clinical Immunology, 2010, 136, 96-104.	3.2	23
54	Peripheral Th-17 cells in allergic rhinitis: New evidence. International Immunopharmacology, 2010, 10, 226-229.	3.8	34

#	Article	IF	CITATIONS
55	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 176-180.	6.5	64

## Modulation of p38 MAPK Activity in Regulatory T Cells after Tolerance with Anti-DNA Ig Peptide in (NZB) Tj ETQq0 $\frac{0.8}{0.8}$ rgBT / $\frac{0.9}{15}$ rgBT / $\frac{0.9}{15}$

57	Serum Leptin Levels in Patients with Pollen-Induced Allergic Rhinitis. International Archives of	2.1	20
	Allergy and Immunology, 2009, 148, 211-218.		
58	Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine, 2009, 27, 3367-3372.	3.8	34
59	Adipokines and sublingual immunotherapy: Preliminary report. Human Immunology, 2009, 70, 73-78.	2.4	7
60	Advancements on phenotypic and functional characterization of non–antigen-specific CD8+CD28â^' regulatory T cells. Human Immunology, 2008, 69, 745-750.	2.4	44
61	Carry-over effect on IFN-gamma production induced by allergen-specific immunotherapy. International Immunopharmacology, 2008, 8, 1622-1625.	3.8	12
62	Serum IL-17 levels in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2008, 122, 650-651.e2.	2.9	52
63	Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. American Journal of Gastroenterology, 2008, 103, 1257-1262.	0.4	114
64	New Therapies in SLE. Recent Patents on Inflammation and Allergy Drug Discovery, 2008, 2, 11-23.	3.6	5
65	CD8+CD28â^' T Regulatory Lymphocytes Inhibiting T Cell Proliferative and Cytotoxic Functions Infiltrate Human Cancers. Journal of Immunology, 2007, 179, 4323-4334.	0.8	207
66	Protection against renal disease in (NZB × NZW)F1 lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis and Rheumatism, 2007, 56, 1945-1953.	6.7	26
67	Prednisone increases apoptosis in <i>in vitro</i> activated human peripheral blood T lymphocytes. Clinical and Experimental Immunology, 2007, 103, 482-490.	2.6	101
68	AIRE gene polymorphisms in systemic sclerosis associated with autoimmune thyroiditis. Clinical Immunology, 2007, 122, 13-17.	3.2	35
69	Gene Vaccination for the Induction of Immune Tolerance. Annals of the New York Academy of Sciences, 2007, 1110, 99-111.	3.8	23
70	Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood, 2006, 107, 1505-1512.	1.4	55
71	Endocrine Regulation of Suppressor Lymphocytes: Role of the Glucocorticoid-Induced TNF-Like Receptor. Annals of the New York Academy of Sciences, 2006, 1069, 377-385.	3.8	12
72	Disruption of immunological tolerance: Role of AIRE gene in autoimmunity. Autoimmunity Reviews, 2006, 5, 145-147.	5.8	46

#	Article	IF	CITATIONS
73	Non-Antigen-Specific CD8+ T Suppressor Lymphocytes in Diseases Characterized by Chronic Immune Responses and Inflammation. Annals of the New York Academy of Sciences, 2005, 1050, 115-123.	3.8	45
74	Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients. Annals of the Rheumatic Diseases, 2004, 63, 210-211.	0.9	13
75	A case of successful pregnancy in a woman with systemic sclerosis treated with cyclosporin. British Journal of Rheumatology, 2004, 43, 1310-1311.	2.3	8
76	Spontaneous transgenesis of human B lymphocytes. Gene Therapy, 2004, 11, 42-51.	4.5	20
77	Non-antigen specific CD8+ T suppressor lymphocytes. Clinical and Experimental Medicine, 2004, 4, 86-92.	3.6	46
78	Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28â^' T cells and inhibit both T-Cell proliferation and CTL function. Human Immunology, 2004, 65, 142-156.	2.4	151
79	Soluble HLAâ€A,â€B,â€C and â€C molecules induce apoptosis in T and NK CD8 <sup>+</sup> cells and inhibit cytotoxic T cell activity through CD8 ligation. European Journal of Immunology, 2003, 33, 125-134.	2.9	338
80	Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and participating in the development of anti-inflammatory functional behavior of phagocytic macrophages. Human Immunology, 2003, 64, 9-20.	2.4	10
81	CD8 T suppressor cells are back to the game: are they players in autoimmunity?. Autoimmunity Reviews, 2002, 1, 279-283.	5.8	97
82	Immune Homeostasis Requires Several Biologic Factors Including Glucocorticoid Hormones. Annals of the New York Academy of Sciences, 2002, 966, 49-63.	3.8	15
83	In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules:do they play a role in autologous blood transfusion?. Transfusion, 2001, 41, 988-996.	1.6	45
84	Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. British Journal of Rheumatology, 2001, 40, 1431-1432.	2.3	39
85	Impairment of CD8+ T Suppressor Cell Function in Patients with Active Systemic Lupus Erythematosus. Journal of Immunology, 2001, 166, 6452-6457.	0.8	160
86	Increased β2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. Tissue Antigens, 2000, 55, 333-341.	1.0	4
87	Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+ T lymphocytes. International Immunology, 2000, 12, 195-203.	4.0	98
88	Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. Human Immunology, 2000, 61, 1347-1351.	2.4	27
89	Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology, 1999, 38, 992-996.	1.9	103
90	lmmune Regulatory Properties of Corticosteroids: Prednisone Induces Apoptosis of Human T Lymphocytes following the CD3 Down-regulation. Annals of the New York Academy of Sciences, 1999, 876, 164-179.	3.8	17

#	Article	IF	CITATIONS
91	Possible Differences in the Mechanism(s) of Action of Different Glucocorticoid Hormone Compounds. Annals of the New York Academy of Sciences, 1999, 876, 193-197.	3.8	17
92	Is there a role for NK cells in the pathogenesis of multiple sclerosis? A case study. Human Immunology, 1999, 60, 231-238.	2.4	4
93	Soluble HLA Class I, HLA Class II, and Fas Ligand in Blood Components: A Possible Key to Explain the Immunomodulatory Effects of Allogeneic Blood Transfusions. Blood, 1999, 93, 1770-1777.	1.4	118
94	Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. European Journal of Immunology, 1998, 28, 3968-3979.	2.9	12
95	Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. Rheumatology, 1997, 36, 244-250.	1.9	16
96	Soluble HLA Class I and Class II Molecule Levels in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Human Immunology, 1997, 54, 54-62.	2.4	32
97	S-adenosil-l-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. International Journal of Immunopharmacology, 1997, 19, 157-165.	1.1	3
98	dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activity. Clinical and Experimental Rheumatology, 1996, 14, 543-50.	0.8	5
99	Increased serum concentration of soluble HLAâ€DR antigens in HIV infection and following transplantation. Tissue Antigens, 1995, 46, 117-123.	1.0	36
100	Major histocompatibility complex class I-restricted presentation of influenza virus nucleoprotein peptide by B lymphoma cells harboring an antibody gene antigenized with the virus peptide. European Journal of Immunology, 1995, 25, 776-783.	2.9	27
101	Interferons up-regulate with different potency HLA class I antigen expression in M14 human melanoma cell line. Possible interaction with glucocorticoid hormones. Cancer Immunology, Immunotherapy, 1995, 41, 23-28.	4.2	11
102	CD4+ Th0 cell clones, isolated from a metastatic lymph node of a melanoma patient, possess cytolytic function. Cancer Immunology, Immunotherapy, 1995, 41, 210-216.	4.2	0
103	DsDNA-Specific T-Cell Lines in Systemic Lupus Erythematosus Patients: Data Suggesting Their Oligoclonality. Annals of the New York Academy of Sciences, 1995, 756, 428-431.	3.8	2
104	Immune cell circulating subsets are affected by gonadal function. Life Sciences, 1994, 54, 1305-1312.	4.3	146
105	Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 1993, 37, 119-124.	4.2	14
106	Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif EMBO Journal, 1993, 12, 4375-4384.	7.8	25
107	Gamma Endorphin and Hla Class I Related Immune Functions. Preliminary Observations. International Journal of Neuroscience, 1990, 51, 181-183.	1.6	0